ACM
ABUS icon

Aster Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Aster Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-292
Closed -$1.41K – 815
2025
Q4 		$1.41K Sell
292
-1,669
-85% -$7.5K ﹤0.01% 988
2025
Q3 		$8.9K Buy
+1,961
New +$7.2K ﹤0.01% 758
2024
Q4 		– Sell
-130
Closed -$501 – 1079
2024
Q3 		$501 Buy
+130
New +$499 ﹤0.01% 1047

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Aster Capital Management's ABUS Position: Q1 2026 in Review

Aster Capital Management sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 292 shares — an estimated $1.41K sold.

Aster Capital Management first reported a position in ABUS in Q3 2024 and held it in 3 quarters. The position peaked at $8.9K in Q3 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Aster Capital Management reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
  • Aster Capital Management sold 292 Arbutus Biopharma shares in Q1 2026, an estimated $1.41K.
  • Aster Capital Management first reported a position in Arbutus Biopharma in Q3 2024 and held it in 3 quarters.
  • Aster Capital Management's Arbutus Biopharma position peaked at $8.9K in Q3 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.